Quoin Pharmaceuticals
Manufacturing · Virginia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
42127 Pleasant Forest Ct, Ashburn, Virgi...Phone Number
(703) 980-4182Website
www.quoinpharma.comRevenue
$9.1 MillionStock Symbol
QNRXIndustry
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Org Chart
Is Quoin Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Quoin Pharmaceuticals is spiking on competitors!
Check if Quoin Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Quoin Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Quoin Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Quoin Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Quoin Pharmaceuticals
Earning: See what the market has to say on Quoin Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Quoin Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Quoin Pharmaceuticals
Find more new buyers
Compare Similar Companies to Quoin Pharmaceuticals
Compare insights from companies similar to Quoin Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Quoin Pharmaceuticals
Company Profile Activity
Activity Insights
Quoin Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Quoin Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Quoin Pharmaceuticals.
Quoin Pharmaceuticals financials insights
Gather financial insights about Quoin Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Stock/Share Issuance
$104.5M
Stock/Share Issuance
$105.3M
Quoin Pharmaceuticals Tech Stack
A closer look at the technologies used by Quoin Pharmaceuticals
Most Recent Scoops
Quoin Pharmaceuticals News & Media
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional aQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Quoin Pharmaceuticals (NASDAQ: QNRX) interim Phase 2/3 data in Netherton Syndrome met the primary endpoint, with four of six patients responding.Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Quoin Pharmaceuticals reports Q2 2026 results, FDA conditional approval of QYLEKI™, and clearance of the first-ever IND for Peeling Skin Syndrome.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases. The company's mission is very simple; to bring hope where there is currently none. The company is totally committed to addressing critical,... Read More